In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NantPharma gets $125mm in early-stage funding from Blackstone

Executive Summary

NantPharma LLC, the pharmaceutical research and manufacturing division of NantWorks LLC (integrating a variety of technologies into new approaches for diagnostic and therapeutic development) has received $125mm from the Blackstone Group in what appears to be the entity’s first financing round. Three partners from Blackstone have joined NantPharma’s board.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies